Abstract
In this review, some important clinical advances presented at the 2011 American Society of Clinical Oncology (ASCO) meeting are summarized. Emerging trends in clinical oncology research are also discussed based on an analysis of the ASCO abstract database in recent years.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
ASCO proceeding, 2011. 1 ASCO proceeding, 2011.
Walker I. & Newell H. Do molecularly targeted agents in oncology have reduced attrition rates? Nature Rev. Drug Discov, 2009; 8:15–16.
Solit DB, Tangen C, and Lara Jr PN. Developing and implementing more informative phase II oncology trials. ASCO educational book 2011; 84–88.
Sharma MR, Stadler WM, and Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011; 103:1093–100.
ASCO online abstract database 2007–2011 (http://www.asco.org/ASCOv2/Meetings/Abstracts).
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Jiao, Xl., Yuan, Yl. & Ziegele, S. Changing paradigms in clinical oncology research — Highlights from the 2011 ASCO annual meeting and beyond. Clin. Oncol. Cancer Res. 8, 202–206 (2011). https://doi.org/10.1007/s11805-011-0581-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11805-011-0581-9